|The TGFBI tgfbi (Catalog #MBS2540240) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The TGFBI Monoclonal Antibody reacts with Human, Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s TGFBI can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA).
IHC: 1:20-1:200. Researchers should empirically determine the suitability of the TGFBI tgfbi for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The TGFBI tgfbi product has the following accession number(s) (GI #4507467) (NCBI Accession #NP_000349.1) (Uniprot Accession #Q15582). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the TGFBI Monoclonal Antibody with the following immunoassay(s):
Western Blot (WB) (Western Blot analysis of extracellularmedia LEC grown for 24 h under normoxia (N), hypoxia (H) or hypoxia and reoxygenation (H/N) for 6 h with TGFBI / BIGH3 Monoclonal Antibody. Silver staining of the membranes was used as loading control.)
TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy. Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).
Immunogen: Fusion protein of TGFBI / BIGH3. Buffer: PBS with 0.1% sodium azide, 50% glycerol, PH7.3
Conjugation: Unconjugated. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing TGFBI are readily searchable from our website. Different antibodies against the same target such as TGFBI may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.